대장암에서 혈중 β1-Integrin의 역할에 대한 연구: 환자-대조군 연구
Role of β1-Integrin in Colorectal Cancer: Case-Control Study
- 주제(키워드) Integrins , Circulating neoplastic cells , Carcinoembryonic antigen , Colorectal neoplasms
- 발행기관 Ewha Womans University School of Medicine
- 발행년도 2017
- 원문페이지 10 p.
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000142241
- 본문언어 한국어
- 저작권 이화여자대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
Objectives: In the metastatic process, interactions between circulating tumor cells (CTCs) and the extracellular matrix or surrounding cells are required. β1-integrin may mediate these interactions. The aim of this study was to investigate whether β1-integrin is associated with the detection of CTCs in colorectal cancer. Methods: We enrolled 30 patients with colorectal cancer (experimental group) and 30 patients with benign diseases (control group). Blood samples were obtained from each group, carcinoembryonic antigen (CEA) mRNA for CTCs marker and β1-integrin mRNA levels were estimated by using reverse transcription-polymerase chain reaction, and the results were compared between the two groups. Results: CEA mRNA was detected more frequently in colorectal cancer patients than in control patients (P=0.008). CEA mRNA was significantly reduced after surgery in the colorectal cancer patients (P=0.032). β1-integrin mRNA was detected more in colorectal cancer patients than in the patients with benign diseases (P<0.001). In colorectal cancer patients, expression of β1-integrin mRNA was detected more for advancedstage cancer than for early-stage cancer (P=0.033) and was significantly decreased after surgery (P<0.001). In addition, expression of β1-integrin mRNA was significantly associated with that of CEA mRNA in colorectal cancer patients (P=0.001). Conclusion: In conclusion, β1-integrin is a potential prognostic factor following surgical resection in colorectal cancer patients. β1-integrin may be a candidate for use as a marker for early detection of micrometastatic tumor cells and for monitoring the therapeutic response in colorectal cancer patients. (Ewha Med J 2017;40(2):77-86)
more